129 related articles for article (PubMed ID: 12768194)
1. Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma.
Cordier Kellerman L; Valeyrie L; Fernandez N; Opolon P; Sabourin JC; Maubec E; Le Roy P; Kane A; Legrand A; Abina MA; Descamps V; Haddada H
Cancer Gene Ther; 2003 Jun; 10(6):481-90. PubMed ID: 12768194
[TBL] [Abstract][Full Text] [Related]
2. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
[TBL] [Abstract][Full Text] [Related]
3. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
[TBL] [Abstract][Full Text] [Related]
4. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM
Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073
[TBL] [Abstract][Full Text] [Related]
5. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
6. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
Kruklitis RJ; Singhal S; Delong P; Kapoor V; Sterman DH; Kaiser LR; Albelda SM
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):123-30. PubMed ID: 14752422
[TBL] [Abstract][Full Text] [Related]
7. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone.
Valle MT; Porta C; Megiovanni AM; Libener R; Mele L; Gaudino G; Strizzi L; Guida R; Toma S; Mutti L
Int J Mol Med; 2003 Feb; 11(2):161-7. PubMed ID: 12525871
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
10. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
13. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis.
duPre' SA; Redelman D; Hunter KW
Exp Mol Pathol; 2008 Dec; 85(3):174-88. PubMed ID: 18929358
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of CD40 ligand gene therapy in malignant mesothelioma.
Friedlander PL; Delaune CL; Abadie JM; Toups M; LaCour J; Marrero L; Zhong Q; Kolls JK
Am J Respir Cell Mol Biol; 2003 Sep; 29(3 Pt 1):321-30. PubMed ID: 12676804
[TBL] [Abstract][Full Text] [Related]
15. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice.
Cao G; Su J; Lu W; Zhang F; Zhao G; Marteralli D; Dong Z
Cancer Gene Ther; 2001 Jul; 8(7):497-505. PubMed ID: 11498771
[TBL] [Abstract][Full Text] [Related]
17. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer.
Ehtesham M; Samoto K; Kabos P; Acosta FL; Gutierrez MA; Black KL; Yu JS
Cancer Gene Ther; 2002 Nov; 9(11):925-34. PubMed ID: 12386831
[TBL] [Abstract][Full Text] [Related]
18. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution.
Jackaman C; Nelson DJ
Cancer Gene Ther; 2010 Jun; 17(6):429-40. PubMed ID: 20150930
[TBL] [Abstract][Full Text] [Related]
20. Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma.
Vehviläinen P; Koli K; Myllärniemi M; Lindholm P; Soini Y; Salmenkivi K; Kinnula VL; Keski-Oja J
Hum Pathol; 2011 Feb; 42(2):269-78. PubMed ID: 21106222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
